董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jonathan F. Finn | 男 | Director | 51 | 未披露 | 未持股 | 2025-10-14 |
| Tessa Cigler | 女 | Director | 51 | 未披露 | 未持股 | 2025-10-14 |
| Steven C. Quay | 男 | Chairman of the Board, President and Chief Executive Officer | 75 | 100.86万美元 | 未持股 | 2025-10-14 |
| Shu Chih Chen | 女 | Director | 64 | 6.58万美元 | 未持股 | 2025-10-14 |
| Stephen J. Galli | 男 | Director | 78 | 9.27万美元 | 未持股 | 2025-10-14 |
| H. Lawrence Remmel | 男 | Lead Independent Director | 73 | 2.46万美元 | 未持股 | 2025-10-14 |
| Richard I. Steinhart | 男 | Director | 67 | 9.07万美元 | 未持股 | 2025-10-14 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Mark Daniel | 男 | Chief Financial Officer and Principal Accounting Officer | 49 | 未披露 | 未持股 | 2025-10-14 |
| Steven C. Quay | 男 | Chairman of the Board, President and Chief Executive Officer | 75 | 100.86万美元 | 未持股 | 2025-10-14 |
董事简历
中英对照 | 中文 | 英文- Jonathan F. Finn
-
Jonathan F. Finn，自2023年11月起担任公司董事。Finn先生自1995年以来一直在投资咨询公司Vantage Consulting Group工作，自2005年起担任Vantage执行副总裁兼首席投资官。在这个角色中，他指导投资策略、资产配置、经理人选择和组合构建。Finn先生还是Scientia Ventures的创始合伙人，Scientia Ventures是风险投资基金的管理者，这些基金投资于以计算生物学和化学、医学数字化、数字疗法和生命科学行业前沿的传统药物开发业务为目标的公司，自2006年以来一直担任这一职务。在其职业生涯的早期，芬恩曾是林德纳共同基金家族的投资组合经理，在2000年至2001年期间担任小型股和资产配置基金的联席经理。他目前担任再生医学企业Verigraft AB、发展阶段专业疼痛公司Rose Pharma LLC和生物能源业务Sol r Bioenergy Holdings AB的董事。Finn先生拥有弗吉尼亚大学经济学学士学位，并拥有特许金融分析师称号。
Jonathan F. Finn,has served as a director of the Company since November 2023. Mr. Finn has worked at Vantage Consulting Group, an investment advisory firm, since 1995 and served as Executive Vice President and Chief Investment Officer at Vantage since 2005. In this role, he directs investment strategy, asset allocation, manager selection and portfolio construction. Mr. Finn is also a Founding Partner of Scientia Ventures, a manager of venture capital funds that invest in companies targeting computational biology and chemistry, the digitization of medicine, digital therapies, and traditional drug development businesses at the cutting edge of the life sciences industry, and has served in this role since 2006. Earlier in his career, Mr. Finn was a portfolio manager for the Lindner family of mutual funds, serving as co-manager for the Small Cap and Asset Allocation funds from 2000 to 2001. He currently serves as director of Verigraft AB, a regenerative medicine venture, Rose Pharma LLC, a development stage specialty pain company, and Solr Bioenergy Holdings AB, a bioenergy business. Mr. Finn has a B.A. in Economics from the University of Virginia and holds the Chartered Financial Analyst designation. - Jonathan F. Finn，自2023年11月起担任公司董事。Finn先生自1995年以来一直在投资咨询公司Vantage Consulting Group工作，自2005年起担任Vantage执行副总裁兼首席投资官。在这个角色中，他指导投资策略、资产配置、经理人选择和组合构建。Finn先生还是Scientia Ventures的创始合伙人，Scientia Ventures是风险投资基金的管理者，这些基金投资于以计算生物学和化学、医学数字化、数字疗法和生命科学行业前沿的传统药物开发业务为目标的公司，自2006年以来一直担任这一职务。在其职业生涯的早期，芬恩曾是林德纳共同基金家族的投资组合经理，在2000年至2001年期间担任小型股和资产配置基金的联席经理。他目前担任再生医学企业Verigraft AB、发展阶段专业疼痛公司Rose Pharma LLC和生物能源业务Sol r Bioenergy Holdings AB的董事。Finn先生拥有弗吉尼亚大学经济学学士学位，并拥有特许金融分析师称号。
- Jonathan F. Finn,has served as a director of the Company since November 2023. Mr. Finn has worked at Vantage Consulting Group, an investment advisory firm, since 1995 and served as Executive Vice President and Chief Investment Officer at Vantage since 2005. In this role, he directs investment strategy, asset allocation, manager selection and portfolio construction. Mr. Finn is also a Founding Partner of Scientia Ventures, a manager of venture capital funds that invest in companies targeting computational biology and chemistry, the digitization of medicine, digital therapies, and traditional drug development businesses at the cutting edge of the life sciences industry, and has served in this role since 2006. Earlier in his career, Mr. Finn was a portfolio manager for the Lindner family of mutual funds, serving as co-manager for the Small Cap and Asset Allocation funds from 2000 to 2001. He currently serves as director of Verigraft AB, a regenerative medicine venture, Rose Pharma LLC, a development stage specialty pain company, and Solr Bioenergy Holdings AB, a bioenergy business. Mr. Finn has a B.A. in Economics from the University of Virginia and holds the Chartered Financial Analyst designation.
- Tessa Cigler
-
Tessa Cigler，于2024年3月加入公司担任董事。Cigler博士是一位医学肿瘤学家，其工作致力于乳腺癌的治疗和预防。Cigler博士于2007年8月加入康乃尔学院，担任威尔康乃尔乳腺中心的医学肿瘤学家和临床调查员。作为威尔康乃尔乳腺中心研究团队的一员，她领导了多项临床试验。Cigler博士在哈佛学院获得本科学位，在杜克大学医学院获得医学博士学位。她还拥有哈佛大学公共卫生学院公共卫生硕士学位。她在纽约长老会医院威尔康乃尔医学中心完成了内科住院医师实习，随后在达纳-法伯哈佛癌症中心获得了医学肿瘤学和血液学研究金。
Tessa Cigler,joined the Company as a director in March 2024. Dr. Cigler is a medical oncologist whose work is dedicated to the treatment and prevention of breast cancer. Dr. Cigler joined the Cornell faculty in August 2007 as a medical oncologist and clinical investigator at the Weill Cornell Breast Center. As a member of the Weill Cornell Breast Center research team, she heads several clinical trials. Dr. Cigler received her undergraduate degree from Harvard College, and her M.D. from Duke University School of Medicine. She also holds a Master's in Public Health from the Harvard School of Public Health. She completed her residency in Internal Medicine at New York Presbyterian Hospital Weill Cornell Medical Center, followed by a fellowship in Medical Oncology and Hematology at the Dana-Farber Harvard Cancer Center. - Tessa Cigler，于2024年3月加入公司担任董事。Cigler博士是一位医学肿瘤学家，其工作致力于乳腺癌的治疗和预防。Cigler博士于2007年8月加入康乃尔学院，担任威尔康乃尔乳腺中心的医学肿瘤学家和临床调查员。作为威尔康乃尔乳腺中心研究团队的一员，她领导了多项临床试验。Cigler博士在哈佛学院获得本科学位，在杜克大学医学院获得医学博士学位。她还拥有哈佛大学公共卫生学院公共卫生硕士学位。她在纽约长老会医院威尔康乃尔医学中心完成了内科住院医师实习，随后在达纳-法伯哈佛癌症中心获得了医学肿瘤学和血液学研究金。
- Tessa Cigler,joined the Company as a director in March 2024. Dr. Cigler is a medical oncologist whose work is dedicated to the treatment and prevention of breast cancer. Dr. Cigler joined the Cornell faculty in August 2007 as a medical oncologist and clinical investigator at the Weill Cornell Breast Center. As a member of the Weill Cornell Breast Center research team, she heads several clinical trials. Dr. Cigler received her undergraduate degree from Harvard College, and her M.D. from Duke University School of Medicine. She also holds a Master's in Public Health from the Harvard School of Public Health. She completed her residency in Internal Medicine at New York Presbyterian Hospital Weill Cornell Medical Center, followed by a fellowship in Medical Oncology and Hematology at the Dana-Farber Harvard Cancer Center.
- Steven C. Quay
-
Steven C. Quay，自2009年4月公司成立以来，他一直担任公司的首席执行官、总裁兼董事会主席。Quay博士获得了美国病理学委员会的解剖病理学认证，在麻省总医院（哈佛医学院教学医院）完成了解剖病理学的实习和住院医师，并且是斯坦福大学医学院病理学系的前教员。他是91项美国专利的发明人，907项美国和国际专利申请的发明人，也是美国食品和药物管理局批准的7种药品专利的发明人。Quay博士于1977年获得医学博士学位，1975年获得Michigan大学博士学位。他于1971年获得Western Michigan大学生物、化学和数学学士学位。
Steven C. Quay,has served as Chief Executive Officer, President and Chairman of the Board of Directors of the Company since the Company was incorporated in April 2009. Dr. Quay is certified in Anatomic Pathology with the American Board of Pathology, has completed both an internship and residency in anatomic pathology at Massachusetts General Hospital, a Harvard Medical School teaching hospital, and is a former faculty member of the Department of Pathology, Stanford University School of Medicine. Dr. Quay is a named inventor on 91 U.S. patents, 907 published US and international patent applications, and is a named inventor on patents covering seven pharmaceutical products that have been approved by the U.S. Food and Drug Administration. Dr. Quay received an M.D. in 1977 and a Ph.D. in 1975 from the University of Michigan. He received his B.A. degree in biology, chemistry and mathematics from Western Michigan University in 1971. He is a director and the Chair of the Governance Committee, of the Taipei-American School in Taipei, Taiwan. - Steven C. Quay，自2009年4月公司成立以来，他一直担任公司的首席执行官、总裁兼董事会主席。Quay博士获得了美国病理学委员会的解剖病理学认证，在麻省总医院（哈佛医学院教学医院）完成了解剖病理学的实习和住院医师，并且是斯坦福大学医学院病理学系的前教员。他是91项美国专利的发明人，907项美国和国际专利申请的发明人，也是美国食品和药物管理局批准的7种药品专利的发明人。Quay博士于1977年获得医学博士学位，1975年获得Michigan大学博士学位。他于1971年获得Western Michigan大学生物、化学和数学学士学位。
- Steven C. Quay,has served as Chief Executive Officer, President and Chairman of the Board of Directors of the Company since the Company was incorporated in April 2009. Dr. Quay is certified in Anatomic Pathology with the American Board of Pathology, has completed both an internship and residency in anatomic pathology at Massachusetts General Hospital, a Harvard Medical School teaching hospital, and is a former faculty member of the Department of Pathology, Stanford University School of Medicine. Dr. Quay is a named inventor on 91 U.S. patents, 907 published US and international patent applications, and is a named inventor on patents covering seven pharmaceutical products that have been approved by the U.S. Food and Drug Administration. Dr. Quay received an M.D. in 1977 and a Ph.D. in 1975 from the University of Michigan. He received his B.A. degree in biology, chemistry and mathematics from Western Michigan University in 1971. He is a director and the Chair of the Governance Committee, of the Taipei-American School in Taipei, Taiwan.
- Shu Chih Chen
-
自本公司于2009年4月注册成立，Shu Chih Chen一直担任首席科学官兼本公司董事。在加盟本公司之前，2008年开始，她担任Ensisheim beginning 总裁。自2006年到2008年，她还是SC2Q Consulting Company 创始人兼总裁。2002年至2006年，担任Nastech Pharmaceuticals Company细胞生物学负责人。在1995年和1996年，她是台北National Yang Ming University一位副教授，并担任NIH RO1的首席研究员在研究部门Nastech制药公司工作之前授予研究肿瘤抑制由间隙连接蛋白43在分子医学系西北医院。她被命名为就有关癌症治疗四项专利申请的发明人。1992年，她获得了Michigan State University 微生物学和公共卫生博士学位，发表了大量关于分子肿瘤学文章。1984年，她获得National Yang Ming University医疗技术理学士学位。
Shu Chih Chen,has served as a director since April 2009. She was a founder of the Company and has served as Chief Scientific Officer of the Company since it was incorporated in April 2009 through August 2014. Prior to joining the Company, she was an Associate Professor at National Yang Ming University, Taipei, Taiwan, and served as the principal investigator of an NIH RO1 grant, studying tumor suppression by gap junction protein connexin 43, at the Department of Molecular Medicine at Northwest Hospital, Seattle, WA. She has two issued U.S. patents and 20 pending U.S. patent applications related to cancer therapeutics. Dr. Chen received her Ph.D. degree in microbiology and public health from Michigan State University in 1992 and has published extensively on molecular oncology. She received her B.S. degree in medical technology from National Yang Ming University, Taipei, Taiwan in 1984. - 自本公司于2009年4月注册成立，Shu Chih Chen一直担任首席科学官兼本公司董事。在加盟本公司之前，2008年开始，她担任Ensisheim beginning 总裁。自2006年到2008年，她还是SC2Q Consulting Company 创始人兼总裁。2002年至2006年，担任Nastech Pharmaceuticals Company细胞生物学负责人。在1995年和1996年，她是台北National Yang Ming University一位副教授，并担任NIH RO1的首席研究员在研究部门Nastech制药公司工作之前授予研究肿瘤抑制由间隙连接蛋白43在分子医学系西北医院。她被命名为就有关癌症治疗四项专利申请的发明人。1992年，她获得了Michigan State University 微生物学和公共卫生博士学位，发表了大量关于分子肿瘤学文章。1984年，她获得National Yang Ming University医疗技术理学士学位。
- Shu Chih Chen,has served as a director since April 2009. She was a founder of the Company and has served as Chief Scientific Officer of the Company since it was incorporated in April 2009 through August 2014. Prior to joining the Company, she was an Associate Professor at National Yang Ming University, Taipei, Taiwan, and served as the principal investigator of an NIH RO1 grant, studying tumor suppression by gap junction protein connexin 43, at the Department of Molecular Medicine at Northwest Hospital, Seattle, WA. She has two issued U.S. patents and 20 pending U.S. patent applications related to cancer therapeutics. Dr. Chen received her Ph.D. degree in microbiology and public health from Michigan State University in 1992 and has published extensively on molecular oncology. She received her B.S. degree in medical technology from National Yang Ming University, Taipei, Taiwan in 1984.
- Stephen J. Galli
-
自2011年7月，Stephen J. Galli, M.D担任本公司董事。他是微生物学与免疫学，医学博士，教授，病理学教授和斯坦福大学医学院系主任，并自1999年2月起任这些职务。在加入斯坦福大学之前，他曾在哈佛医学院的教授。他拥有13项美国专利，并拥有超过340出版物。他是American Society for Investigative Pathology前任会长和 Collegium Internationale AllergologicumCollegium现任会长。除了接受奖项，他的研究，他最近被确认通过多样性，2010年斯坦福大学校长卓越奖为他的招聘和支持妇女和未被充分代表的少数民族在斯坦福大学。1986年，他以优异成绩获得哈佛学院生物学文学士，1973年获得哈佛医学院医学博士学位，1977年，Massachusetts General Hospital 完成在病理解剖。
Stephen J. Galli,has served as a director of the Company since July 2011. Dr. Galli has been a Professor of Pathology and of Microbiology & Immunology and the Mary Hewitt Loveless, M.D., Professor, at Stanford University School of Medicine, Stanford, California since February 1999. He served as Chair of the Department of Pathology at Stanford University School of Medicine from 1999 to 2016. Before joining Stanford, he was on the faculty of Harvard Medical School. He holds 16 U.S. patents and has over 490 publications. He is the past president of the American Society for Investigative Pathology, the past president of the Collegium Internationale Allergologicum, and the past president of the Pluto Club (Association of University Pathologists). In addition to receiving several awards for his research, and being elected to the National Academy of Medicine (USA), the Accademia Nazionale de Lincei (Rome, Italy), and the American Clinical and Climatological Association, he was recognized with the 2010 Stanford University President's Award for Excellence through Diversity for his recruitment and support of women and underrepresented minorities at Stanford University. He received his B.A. degree in biology, magna cum laude, from Harvard College in 1968 and his M.D. degree from Harvard Medical School in 1973 and completed a residency in anatomic pathology at the Massachusetts General Hospital in 1977. - 自2011年7月，Stephen J. Galli, M.D担任本公司董事。他是微生物学与免疫学，医学博士，教授，病理学教授和斯坦福大学医学院系主任，并自1999年2月起任这些职务。在加入斯坦福大学之前，他曾在哈佛医学院的教授。他拥有13项美国专利，并拥有超过340出版物。他是American Society for Investigative Pathology前任会长和 Collegium Internationale AllergologicumCollegium现任会长。除了接受奖项，他的研究，他最近被确认通过多样性，2010年斯坦福大学校长卓越奖为他的招聘和支持妇女和未被充分代表的少数民族在斯坦福大学。1986年，他以优异成绩获得哈佛学院生物学文学士，1973年获得哈佛医学院医学博士学位，1977年，Massachusetts General Hospital 完成在病理解剖。
- Stephen J. Galli,has served as a director of the Company since July 2011. Dr. Galli has been a Professor of Pathology and of Microbiology & Immunology and the Mary Hewitt Loveless, M.D., Professor, at Stanford University School of Medicine, Stanford, California since February 1999. He served as Chair of the Department of Pathology at Stanford University School of Medicine from 1999 to 2016. Before joining Stanford, he was on the faculty of Harvard Medical School. He holds 16 U.S. patents and has over 490 publications. He is the past president of the American Society for Investigative Pathology, the past president of the Collegium Internationale Allergologicum, and the past president of the Pluto Club (Association of University Pathologists). In addition to receiving several awards for his research, and being elected to the National Academy of Medicine (USA), the Accademia Nazionale de Lincei (Rome, Italy), and the American Clinical and Climatological Association, he was recognized with the 2010 Stanford University President's Award for Excellence through Diversity for his recruitment and support of women and underrepresented minorities at Stanford University. He received his B.A. degree in biology, magna cum laude, from Harvard College in 1968 and his M.D. degree from Harvard Medical School in 1973 and completed a residency in anatomic pathology at the Massachusetts General Hospital in 1977.
- H. Lawrence Remmel
-
自2012年2月，H. Lawrence Remmel, Esq担任本公司董事。现任Pryor Cashman LLP律师事务所合伙人，位于纽约市，在那里他主持的银行和金融业务团队。 他于1988年加盟Pryor Cashman。他的业务包括企业和银行融资，与1940实行的投资公司法和知识产权和许可问题等，特别是在生物技术和biocosmeceutical领域。 他担任CytoDel，LLC的顾问，是一家早期阶段的生物制药公司，开发的产品用于生物防御，神经学药物输送和美容医学。他是Reboul, MacMurray, Hewitt, Maynard & Kristol合伙人，从1984年至1988年。他在Carter, Ledyard & Milburn开始了他的律师生涯，1979年至1984年，是公司的合伙人。他于1980年被录取到纽约酒吧，是纽约州律师协会的会员。他于1979年获得Washington & Lee University School of Law 法学博士学位，1975年获得Princeton University 学士学位。
H. Lawrence Remmel,has served as a director of the Company since February 2012, and as Lead Independent Director since 2024. He is currently a partner of the law firm Pryor Cashman LLP, located in New York City, where he chairs the Banking and Finance practice group. Mr. Remmel joined Pryor Cashman in 1988. His practice includes corporate and banking financings, issues relating to the Investment Company Act of 1940, and intellectual property and licensing issues, in particular in the biotechnology and biocosmeceutical areas. Mr. Remmel previously served on the Board of Advisors of CytoDel, LLC, an early-stage bio-pharmaceutical company developing products for bio-defense, neuronal drug delivery, and musculoskeletal and aesthetic medicine. In February 2018, he became a director of CytoDel, Inc., the successor to CytoDel LLC. In March 2019, he became a director of Aufbau Holdings Limited, an Irish limited company, developing therapeutics in ophthalmology and other areas. He was an associate of the law firm Reboul, MacMurray, Hewitt, Maynard & Kristol from 1984 to 1988, and began his legal career at Carter, Ledyard & Milburn, where he was an associate from 1979 to 1984. He was admitted to the New York bar in 1980 and is a member of the New York State Bar Association. He received his J.D. from the Washington & Lee University School of Law in 1979 and his B.A. from Princeton University in 1975. He currently is a doctoral candidate in the Graduate School of Life Sciences of the University of Utrecht, in the Department of Clinical and Translational Oncology, with a thesis project in novel diagnostics and therapies for early-stage breast cancer. - 自2012年2月，H. Lawrence Remmel, Esq担任本公司董事。现任Pryor Cashman LLP律师事务所合伙人，位于纽约市，在那里他主持的银行和金融业务团队。 他于1988年加盟Pryor Cashman。他的业务包括企业和银行融资，与1940实行的投资公司法和知识产权和许可问题等，特别是在生物技术和biocosmeceutical领域。 他担任CytoDel，LLC的顾问，是一家早期阶段的生物制药公司，开发的产品用于生物防御，神经学药物输送和美容医学。他是Reboul, MacMurray, Hewitt, Maynard & Kristol合伙人，从1984年至1988年。他在Carter, Ledyard & Milburn开始了他的律师生涯，1979年至1984年，是公司的合伙人。他于1980年被录取到纽约酒吧，是纽约州律师协会的会员。他于1979年获得Washington & Lee University School of Law 法学博士学位，1975年获得Princeton University 学士学位。
- H. Lawrence Remmel,has served as a director of the Company since February 2012, and as Lead Independent Director since 2024. He is currently a partner of the law firm Pryor Cashman LLP, located in New York City, where he chairs the Banking and Finance practice group. Mr. Remmel joined Pryor Cashman in 1988. His practice includes corporate and banking financings, issues relating to the Investment Company Act of 1940, and intellectual property and licensing issues, in particular in the biotechnology and biocosmeceutical areas. Mr. Remmel previously served on the Board of Advisors of CytoDel, LLC, an early-stage bio-pharmaceutical company developing products for bio-defense, neuronal drug delivery, and musculoskeletal and aesthetic medicine. In February 2018, he became a director of CytoDel, Inc., the successor to CytoDel LLC. In March 2019, he became a director of Aufbau Holdings Limited, an Irish limited company, developing therapeutics in ophthalmology and other areas. He was an associate of the law firm Reboul, MacMurray, Hewitt, Maynard & Kristol from 1984 to 1988, and began his legal career at Carter, Ledyard & Milburn, where he was an associate from 1979 to 1984. He was admitted to the New York bar in 1980 and is a member of the New York State Bar Association. He received his J.D. from the Washington & Lee University School of Law in 1979 and his B.A. from Princeton University in 1975. He currently is a doctoral candidate in the Graduate School of Life Sciences of the University of Utrecht, in the Department of Clinical and Translational Oncology, with a thesis project in novel diagnostics and therapies for early-stage breast cancer.
- Richard I. Steinhart
-
Richard I. Steinhart，自2014年3月起担任本公司董事。他目前是BioXcel Therapeutics， Inc.（临床阶段生物制药公司）的高级副总裁兼首席财务官，他于2017年10月加入该公司。从2015年10月到2017年6月，他担任私人控股制药公司Remedy Pharmaceuticals， Inc.的副总裁兼首席财务官。从2014年1月到加入Remedy Pharmaceuticals，他担任生物技术和医疗设备行业的多家公司的独立财务顾问。从2006年4月到2013年12月，他是MELA Sciences， Inc.的高管，担任其高级副总裁、首席财务官、财务主管和秘书。1992年至2006年，他担任Forest St. Capital/SAE Ventures的董事总经理。此前，他曾担任Emisphere Technologies的副总裁兼首席财务官（1991年至1992年），以及CW Group Inc.的普通合伙人兼首席财务官。他是Actinium Pharmaceuticals的董事会成员，担任审计委员会主席。2004年至2012年，他是Manhattan Pharmaceuticals的董事会成员，并担任审计委员会主席。他在Pace大学获得工商管理硕士和工商管理硕士学位。
Richard I. Steinhart,has served as a director of the Company since March 2014. Mr. Steinhart is currently the Senior Vice President and Chief Financial Officer of BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company, which he joined in October 2017. From October 2015 to June 2017, he was Vice President and Chief Financial Officer of Remedy Pharmaceuticals, Inc., a privately held pharmaceuticals company. From January 2014 until he joined Remedy Pharmaceuticals, Mr. Steinhart acted as an independent financial consultant to various companies in the biotechnology and medical device industries. From April 2006 to December 2013, Mr. Steinhart was an executive at MELA Sciences, Inc., serving as its Senior Vice President, Chief Financial Officer, Treasurer and Secretary. From 1992 to 2006, Mr. Steinhart was Managing Director at Forest St. Capital/SAE Ventures. Earlier, he served as Vice President and Chief Financial Officer at Emisphere Technologies from 1991 to 1992 and as General Partner and Chief Financial Officer of CW Group Inc. Mr. Steinhart is a member of the Board of Directors of Actinium Pharmaceuticals where he is Chairman of the Audit Committee. From 2004 to 2012, Mr. Steinhart was a member of the Board of Directors of Manhattan Pharmaceuticals and was Chairman of the Audit Committee. Mr. Steinhart received his B.B.A. and M.B.A. degrees from Pace University. - Richard I. Steinhart，自2014年3月起担任本公司董事。他目前是BioXcel Therapeutics， Inc.（临床阶段生物制药公司）的高级副总裁兼首席财务官，他于2017年10月加入该公司。从2015年10月到2017年6月，他担任私人控股制药公司Remedy Pharmaceuticals， Inc.的副总裁兼首席财务官。从2014年1月到加入Remedy Pharmaceuticals，他担任生物技术和医疗设备行业的多家公司的独立财务顾问。从2006年4月到2013年12月，他是MELA Sciences， Inc.的高管，担任其高级副总裁、首席财务官、财务主管和秘书。1992年至2006年，他担任Forest St. Capital/SAE Ventures的董事总经理。此前，他曾担任Emisphere Technologies的副总裁兼首席财务官（1991年至1992年），以及CW Group Inc.的普通合伙人兼首席财务官。他是Actinium Pharmaceuticals的董事会成员，担任审计委员会主席。2004年至2012年，他是Manhattan Pharmaceuticals的董事会成员，并担任审计委员会主席。他在Pace大学获得工商管理硕士和工商管理硕士学位。
- Richard I. Steinhart,has served as a director of the Company since March 2014. Mr. Steinhart is currently the Senior Vice President and Chief Financial Officer of BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company, which he joined in October 2017. From October 2015 to June 2017, he was Vice President and Chief Financial Officer of Remedy Pharmaceuticals, Inc., a privately held pharmaceuticals company. From January 2014 until he joined Remedy Pharmaceuticals, Mr. Steinhart acted as an independent financial consultant to various companies in the biotechnology and medical device industries. From April 2006 to December 2013, Mr. Steinhart was an executive at MELA Sciences, Inc., serving as its Senior Vice President, Chief Financial Officer, Treasurer and Secretary. From 1992 to 2006, Mr. Steinhart was Managing Director at Forest St. Capital/SAE Ventures. Earlier, he served as Vice President and Chief Financial Officer at Emisphere Technologies from 1991 to 1992 and as General Partner and Chief Financial Officer of CW Group Inc. Mr. Steinhart is a member of the Board of Directors of Actinium Pharmaceuticals where he is Chairman of the Audit Committee. From 2004 to 2012, Mr. Steinhart was a member of the Board of Directors of Manhattan Pharmaceuticals and was Chairman of the Audit Committee. Mr. Steinhart received his B.B.A. and M.B.A. degrees from Pace University.
高管简历
中英对照 | 中文 | 英文- Mark Daniel
Mark Daniel，是一位资深的金融领导者，在构建支持全球生命科学业务收入规模的预测节奏、系统和上市公司学科方面拥有超过25年的经验。最近，从2017年到2025年，Daniel先生在布鲁克 Spatial Biology，Inc.担任财务高级副总裁。从2014年到2016年，Daniel先生担任Newyu，Inc.（前身为Numera，Inc.）的首席财务官。Daniel先生在华盛顿州立大学获得了工商管理学士学位，会计学重点。
Mark Daniel,is a senior finance leader with more than 25 years of experience building the forecasting cadence, systems, and public-company discipline that support revenue scale in global life-science businesses. Most recently, from 2017 until 2025, Mr. Daniel served as Senior Vice President, Finance at Bruker Spatial Biology, Inc. From 2014 until 2016, Mr. Daniel served as Chief Financial Officer of Newyu, Inc. (formerly Numera, Inc.). Mr. Daniel earned a B.S. degree in Business Administration, Accounting Emphasis from Washington State University.- Mark Daniel，是一位资深的金融领导者，在构建支持全球生命科学业务收入规模的预测节奏、系统和上市公司学科方面拥有超过25年的经验。最近，从2017年到2025年，Daniel先生在布鲁克 Spatial Biology，Inc.担任财务高级副总裁。从2014年到2016年，Daniel先生担任Newyu，Inc.（前身为Numera，Inc.）的首席财务官。Daniel先生在华盛顿州立大学获得了工商管理学士学位，会计学重点。
- Mark Daniel,is a senior finance leader with more than 25 years of experience building the forecasting cadence, systems, and public-company discipline that support revenue scale in global life-science businesses. Most recently, from 2017 until 2025, Mr. Daniel served as Senior Vice President, Finance at Bruker Spatial Biology, Inc. From 2014 until 2016, Mr. Daniel served as Chief Financial Officer of Newyu, Inc. (formerly Numera, Inc.). Mr. Daniel earned a B.S. degree in Business Administration, Accounting Emphasis from Washington State University.
- Steven C. Quay
Steven C. Quay，自2009年4月公司成立以来，他一直担任公司的首席执行官、总裁兼董事会主席。Quay博士获得了美国病理学委员会的解剖病理学认证，在麻省总医院（哈佛医学院教学医院）完成了解剖病理学的实习和住院医师，并且是斯坦福大学医学院病理学系的前教员。他是91项美国专利的发明人，907项美国和国际专利申请的发明人，也是美国食品和药物管理局批准的7种药品专利的发明人。Quay博士于1977年获得医学博士学位，1975年获得Michigan大学博士学位。他于1971年获得Western Michigan大学生物、化学和数学学士学位。
Steven C. Quay,has served as Chief Executive Officer, President and Chairman of the Board of Directors of the Company since the Company was incorporated in April 2009. Dr. Quay is certified in Anatomic Pathology with the American Board of Pathology, has completed both an internship and residency in anatomic pathology at Massachusetts General Hospital, a Harvard Medical School teaching hospital, and is a former faculty member of the Department of Pathology, Stanford University School of Medicine. Dr. Quay is a named inventor on 91 U.S. patents, 907 published US and international patent applications, and is a named inventor on patents covering seven pharmaceutical products that have been approved by the U.S. Food and Drug Administration. Dr. Quay received an M.D. in 1977 and a Ph.D. in 1975 from the University of Michigan. He received his B.A. degree in biology, chemistry and mathematics from Western Michigan University in 1971. He is a director and the Chair of the Governance Committee, of the Taipei-American School in Taipei, Taiwan.- Steven C. Quay，自2009年4月公司成立以来，他一直担任公司的首席执行官、总裁兼董事会主席。Quay博士获得了美国病理学委员会的解剖病理学认证，在麻省总医院（哈佛医学院教学医院）完成了解剖病理学的实习和住院医师，并且是斯坦福大学医学院病理学系的前教员。他是91项美国专利的发明人，907项美国和国际专利申请的发明人，也是美国食品和药物管理局批准的7种药品专利的发明人。Quay博士于1977年获得医学博士学位，1975年获得Michigan大学博士学位。他于1971年获得Western Michigan大学生物、化学和数学学士学位。
- Steven C. Quay,has served as Chief Executive Officer, President and Chairman of the Board of Directors of the Company since the Company was incorporated in April 2009. Dr. Quay is certified in Anatomic Pathology with the American Board of Pathology, has completed both an internship and residency in anatomic pathology at Massachusetts General Hospital, a Harvard Medical School teaching hospital, and is a former faculty member of the Department of Pathology, Stanford University School of Medicine. Dr. Quay is a named inventor on 91 U.S. patents, 907 published US and international patent applications, and is a named inventor on patents covering seven pharmaceutical products that have been approved by the U.S. Food and Drug Administration. Dr. Quay received an M.D. in 1977 and a Ph.D. in 1975 from the University of Michigan. He received his B.A. degree in biology, chemistry and mathematics from Western Michigan University in 1971. He is a director and the Chair of the Governance Committee, of the Taipei-American School in Taipei, Taiwan.